RICE-ibrutinib in Relapsed DLBCL

  • End date
    Aug 21, 2023
  • participants needed
  • sponsor
    Singapore General Hospital
Updated on 27 January 2022
gilbert's syndrome
glomerular filtration rate
neutrophil count
b-cell lymphoma
refractory diffuse large b-cell lymphoma
diffuse large b-cell lymphoma refractory


This is a multicentre, open-label, phase II study of ibrutinib 560 mg in combination with R-ICE for treatment of transplant-eligible relapsed/refractory diffuse large B-cell lymphoma.


All patients will receive R-ICE therapy for 2 cycles followed by PET-CT assessment (PET-2). Ibrutinib 560 mg will be added to the RICE regimen based on results of PET-2 as follows:

  • Patients in CR will continue with 2 more cycles of R-ICE and proceed onto ASCT. These patients will not receive ibrutinib.
  • In patients with stable disease or achieving a response that is less than CR, ibrutinib 560 mg will be added. The combination of ibrutinib-RICE will be given for 2 cycles and will be followed by PET-CT assessment (PET-4). Patients who achieve PR at this point will proceed onto ASCT.
  • Patients who have disease progression will be removed from the trial. Hematopoietic stem cell harvesting can be performed following count recovery at any cycle of R-ICE, but preferably cycle 2.

Transplant conditioning regimen will be with standard BEAM chemotherapy (carmustine, etoposide, cytarabine, melphalan).

Following ASCT, ibrutinib will be given as maintenance therapy for patients who did not achieve a CR at the time of PET-2 assessment. This will be continued for up to 1 year after ASCT.

Condition Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma Recurrent
Treatment Ibrutinib-RICE
Clinical Study IdentifierNCT02955628
SponsorSingapore General Hospital
Last Modified on27 January 2022


Yes No Not Sure

Inclusion Criteria

Histologically proven relapsed or refractory DLBCL (including transformed DLBCL)
Patients who are eligible for autologous stem cell transplant as deemed by the Bone Marrow Transplant Team in the participating cites
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix A)
Minimum life expectancy of 6 months
Previously treated with anthracycline-based chemotherapy (unless contraindicated) with rituximab Written informed consent
Must be at least 21 years old and able to sign informed consent form
Adequate hematological function within 30 days prior to signing informed consent
Absolute neutrophil count (ANC) 1.0 x 109/L (1000/mm3) independent of growth factor support
Platelets 100,000/mm3 or 50,000/mm3 if bone marrow involvement independent of transfusion support in either situation
Hemoglobin 8 g/dL
Biochemical values within the following limits
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 x upper limit of normal (ULN)
Total bilirubin 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin
Serum creatinine 2 x ULN or estimated Glomerular Filtration Rate (Cockroft Gault) 40 mL/min/1.73m2
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study
Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study
Must be able to adhere to study visit schedules and other protocol requirements
Male subject agrees to use an acceptable method for contraception for the duration of the study

Exclusion Criteria

Concomitant use of any other investigational agent
Contraindication to any drug contained in the regimen
Myocardial infarction within 6 months prior to enrolment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant
Clinically significant active infection
Patients who are pregnant or breast-feeding
Coexistent second malignancy or history of prior malignancy within previous 3 years (excluding non-melanoma skin tumors or in situ carcinoma of the cervix)
Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures
Major surgery within 4 weeks of randomization
Known central nervous system lymphoma
History of stroke or intracranial hemorrhage within 6 months prior to randomization
Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon)
Requires treatment with strong CYP3A inhibitors
Known inherited platelet function disorder
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
Vaccinated with live, attenuated vaccines within 4 weeks of randomization
Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or active Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note